KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Intangibles (2016 - 2025)

Abbott Laboratories' Intangibles history spans 16 years, with the latest figure at $6.3 billion for Q1 2025.

  • For Q1 2025, Intangibles changed N/A year-over-year to $6.3 billion; the TTM value through Mar 2025 reached $6.3 billion, changed N/A, while the annual FY2024 figure was $6.6 billion, N/A changed from the prior year.
  • Intangibles for Q1 2025 was $6.3 billion at Abbott Laboratories, down from $6.6 billion in the prior quarter.
  • Across five years, Intangibles topped out at $27.8 billion in Q2 2021 and bottomed at $6.3 billion in Q1 2025.
  • The 4-year median for Intangibles is $10.5 billion (2022), against an average of $15.8 billion.
  • The largest annual shift saw Intangibles skyrocketed 2216.67% in 2021 before it plummeted 62.26% in 2022.
  • A 4-year view of Intangibles shows it stood at $27.7 billion in 2021, then tumbled by 62.26% to $10.5 billion in 2022, then crashed by 36.42% to $6.6 billion in 2024, then decreased by 5.81% to $6.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Intangibles are $6.3 billion (Q1 2025), $6.6 billion (Q4 2024), and $10.5 billion (Q4 2022).